Arnica

This is arnica’s strongest human indication, and it rests on the topical preparation the herb is actually used as. A randomised, double-blind trial in 204 patients with radiologically confirmed hand osteoarthritis found an arnica tincture gel (50 g tincture/100 g, DER 1:20) not inferior to 5% ibuprofen gel for pain and hand function over 21 days, with similar adverse-event rates ^{1Reference 1Widrig et al. · 2007RCTChoosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study — randomised, double-blindView study →}. An earlier open, multicenter study of a fresh-plant arnica gel in 79 patients with mild-to-moderate knee OA reported significant WOMAC improvements in pain, stiffness and function at 3 and 6 weeks, with good tolerability ^{2Reference 2Knuesel et al. · 2002Clinical trialArnica montana gel in osteoarthritis of the knee: an open, multicenter clinical trial — clinical trialView study →}. The honest limitation is design: one was an active-comparator non-inferiority trial and the other was uncontrolled — neither included a placebo arm, so the effect size relative to no treatment is unquantified.

Gap: no placebo-controlled RCT of topical arnica in OA exists, so “as good as ibuprofen gel” is the ceiling of what can be claimed — and the ibuprofen comparator was itself topical.

Arnica’s anti-inflammatory action has a defined molecular mechanism, which is rare for a herbal preparation. The sesquiterpene lactone helenalin selectively inhibits the transcription factor NF-κB — not by blocking IκB degradation as older models proposed, but by directly alkylating the p65 subunit, preventing it from binding DNA ^{3Reference 3Lyss et al. · 1998In vitroThe anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65 — in vitroView study →}. Arnica flower preparations inhibit NF-κB and NF-AT activation and reduce croton-oil-induced ear edema in mice, with potency tracking the sesquiterpene-lactone content and the esterification pattern of dihydrohelenalin derivatives ^{4Reference 4Klaas et al. · 2002In vitroStudies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers — in vitro / animal model (mouse ear edema)View study →}. These lactones do penetrate the stratum corneum from alcoholic tinctures and fresh-plant gels, supporting topical delivery ^{19Reference 19Wagner et al. · 2004In vitroSkin penetration studies of Arnica preparations and of their sesquiterpene lactones — in vitroView study →}. Potency depends heavily on chemotype and preparation: European populations split into helenalin-dominant and dihydrohelenalin-dominant chemotypes, and total sesquiterpene-lactone content rises with flower maturity and is concentrated in the disk florets ^{20,21Reference 20Perry et al. · 2009Sesquiterpene lactones in Arnica montana: helenalin and dihydrohelenalin chemotypes in SpainView study →Reference 21Douglas et al. · 2004Sesquiterpene lactones in Arnica montana: a rapid analytical method and the effects of flower maturity and simulated mechanical harvesting on quality and yieldView study →}. The human OA and DOMS signals are the clinical read-out of this pathway.

Gap: the mechanism is proven in vitro and in mouse edema; there is no human anti-inflammatory biomarker trial, and effect depends heavily on chemotype and preparation.

Results are genuinely mixed, and concentration seems to matter. A rater-blinded RCT using standardised pulsed-dye-laser bruises found a 20% arnica topical produced significantly faster bruise resolution than white petrolatum (and better than a vitamin-K/retinol mix), though not better than 5% vitamin K ^{5Reference 5Leu et al. · 2010RCTAccelerated resolution of laser-induced bruising with topical 20% arnica: a rater-blinded randomised controlled trial — randomisedView study →}. A separate double-blind, placebo-controlled trial of an arnica gel on post-laser facial bruising found no significant difference versus vehicle ^{6Reference 6Alonso et al. · 2002RCTEffects of topical arnica gel on post-laser treatment bruises — randomised, placebo-controlledView study →}. Systematic reviews of arnica for post-procedure ecchymosis conclude the data are insufficient and inconsistent ^{18Reference 18Tao et al. · 2022ReviewHomeopathic agents or vitamins in reducing ecchymosis after oculofacial surgery: a report by the American Academy of Ophthalmology — reviewView study →}. Note that most “arnica for bruising” trials test oral homeopathic arnica, which is a separate preparation and does not support the topical herbal claim ^{16,18Reference 16Ernst et al. · 1998Systematic reviewEfficacy of homeopathic arnica: a systematic review of placebo-controlled clinical trials — systematic reviewView study →Reference 18Tao et al. · 2022ReviewHomeopathic agents or vitamins in reducing ecchymosis after oculofacial surgery: a report by the American Academy of Ophthalmology — reviewView study →}.

Gap: the positive signal appears tied to high-concentration (20%) topicals; lower-strength gels have failed, and no trial has standardised the preparation across studies.

Ethanolic extracts of arnica flowers are rich in phenolics and flavonoids and show measurable free-radical scavenging (DPPH, ORAC, Trolox-equivalent assays). In a mouse fibroblast (NCTC) model, arnica extract protected cells against hydrogen-peroxide-induced oxidative damage at 10 mg/L, preserving viability and morphology ^{7Reference 7Craciunescu et al. · 2012In vitroEvaluation of antioxidant and cytoprotective activities of Arnica montana L. and Artemisia absinthium L. ethanolic extracts — in vitroView study →}. The activity is attributed largely to quercetin and its glycosides. This is a plausible contributor to the herb’s topical wound/skin-protective reputation, but the evidence is entirely at the cell-and-chemistry level.

Gap: in vitro and single-cell-line only; notably, a companion Artemisia absinthium extract outperformed arnica in the same assays ^{7Reference 7Craciunescu et al. · 2012In vitroEvaluation of antioxidant and cytoprotective activities of Arnica montana L. and Artemisia absinthium L. ethanolic extracts — in vitroView study →}, and there is no human antioxidant outcome.

One double-blind, randomised, placebo-controlled trial tested topical arnica in 20 well-trained men after a downhill-running protocol designed to induce delayed-onset muscle soreness, reapplied every 4 waking hours ^{8Reference 8Pumpa et al. · 2014RCTThe effects of topical Arnica on performance, pain and muscle damage after intense eccentric exercise — randomised, placebo-controlledView study →}. The arnica group reported less pain (VAS and muscle tenderness) at 72 hours post-exercise. However, arnica had no effect on any performance measure (peak torque, jump height) or on blood markers of muscle damage and inflammation (creatine kinase, myoglobin, IL-1β, IL-6, TNF-α, CRP).

Gap: a single small trial (n=20) showing a subjective-pain benefit with no objective correlate — the analgesic reading is real but unreplicated and not matched by any biochemical change.

Arnica extract shows activity against oral micro-organisms in vitro. A 10% w/v Arnica montana extract produced growth-inhibition zones by agar diffusion against a panel including Streptococcus mutans, Staphylococcus aureus and Candida albicans, and affected mutans-streptococcal adherence, in a comparison with propolis ^{9Reference 9Koo et al. · 2000In vitroIn vitro antimicrobial activity of propolis and Arnica montana against oral pathogens — in vitroView study →}. Review-level summaries repeat antibacterial and antifungal activity as a class property of the extract ^{13Reference 13Kriplani et al. · 2017ReviewArnica montana L. — a plant of healing: review — reviewView study →}.

Gap: in vitro agar-diffusion data only, at whole-extract concentrations; no in vivo infection model and no clinical antimicrobial use.

This is a laboratory phenomenon of the isolated constituent, not a use of the herb. Purified helenalin induces apoptosis in leukemia (Jurkat) T cells at 10-50 µM — independent of the CD95 death receptor and not blocked by Bcl-2/Bcl-xL overexpression — via caspase-3/-8 activation ^{10Reference 10Dirsch et al. · 2001In vitroHelenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-xL or Bcl-2 — in vitroView study →}, a property shared with related sesquiterpene lactones ^{11Reference 11Dirsch et al. · 2001In vitroCytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis — in vitroView study →}. The same NF-κB p65 repression that drives its anti-inflammatory action also triggers autophagic cell death in cancer cells ^{12Reference 12Lim et al. · 2012In vitroNF-κB p65 repression by the sesquiterpene lactone, helenalin, contributes to the induction of autophagy cell death — in vitroView study →}. Because helenalin is systemically toxic and arnica is restricted to external use on intact skin ^{22,23Reference 22Cosmetic Ingredient Review Expert Panel · 2001ReviewFinal report on the safety assessment of Arnica montana extract and Arnica montanaView study →Reference 23Blumenthal · 1998ReviewThe Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicine — pharmacopoeial monograph (external use only)}, none of this represents a therapeutic anticancer application of the herb.

Gap: cell-line only, at micromolar concentrations of an isolated toxic constituent — there is no whole-herb, in vivo, or clinical anticancer evidence, and the route of use precludes it.

A methanolic extract of Arnica montana flowerheads showed moderate anti-acetylcholinesterase activity in vitro, alongside antioxidant capacity ^{24Reference 24Zheleva-Dimitrova et al. · 2012In vitroAntioxidant and acetylcholinesterase inhibitory potential of Arnica montana cultivated in Bulgaria — in vitroView study →}. Because cholinesterase inhibitors are used symptomatically in Alzheimer’s disease, this has been floated as a neurological angle — but the leap from an enzyme assay to cognitive benefit is entirely unmade, and much of the cholinesterase literature in this genus concerns the related species Arnica chamissonis, not A. montana.

Gap: a single in vitro extract assay with no animal, human, or even whole-preparation follow-up; the Alzheimer’s framing is inference, not evidence.

Arnica is a topical-only herb: it is applied to intact skin as a gel, cream, oil or tincture and must not be taken internally, because its sesquiterpene lactone helenalin is toxic and can cause severe gastroenteritis, cardiac arrhythmia and organ damage if ingested ^{22,23Reference 22Cosmetic Ingredient Review Expert Panel · 2001ReviewFinal report on the safety assessment of Arnica montana extract and Arnica montanaView study →Reference 23Blumenthal · 1998ReviewThe Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicine — pharmacopoeial monograph (external use only)}. It should not be applied to broken skin or open wounds — the sesquiterpene lactones penetrate the stratum corneum and reach the circulation from alcoholic preparations ^{19Reference 19Wagner et al. · 2004In vitroSkin penetration studies of Arnica preparations and of their sesquiterpene lactones — in vitroView study →} — nor near the eyes.

As a member of the Asteraceae (daisy) family, arnica can provoke allergic contact dermatitis and cross-reactivity in people sensitised to ragweed, chamomile, marigold or related plants; this is the most common real-world adverse effect, and prolonged or repeated topical use raises the risk ^{22Reference 22Cosmetic Ingredient Review Expert Panel · 2001ReviewFinal report on the safety assessment of Arnica montana extract and Arnica montanaView study →}. The German Commission E restricts arnica to external application on unbroken skin ^{23Reference 23Blumenthal · 1998ReviewThe Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicine — pharmacopoeial monograph (external use only)}. Homeopathic ultra-dilutions of arnica are a separate, non-herbal preparation and are not covered by these cautions.

Scope note: no herb–drug interaction studies were identified for arnica — the only interaction concern is theoretical (systemic helenalin absorbed through broken skin), so interactions are best described as not assessed rather than absent.

Contraindications: Do not take internally.